-
Prescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis
In September 2019, Health Canada directed domestic manufacturers to cease distributing ranitidine due to potentially high concentrations of the possible carcinogen N-nitrosodimethylamine (NDMA). This study will characterize the use of dispensed histamine-2 receptor antagonists (H2RAs) in Canada by describing demographic and clinical characteristics of users and prescribers.
Q20-12Validity of diagnoses of SARS-CoV-2 infection in Canadian administrative health data: a multiprovince, population-based cohort study
This multi-province validation study supports the use of inpatient and ED records as alternatives to population- based laboratory tests for identification of COVID-19 cases during the first year of the pandemic.
Our findings do not support the use of outpatient service claims to identify people infected with COVID-19.Q21-04Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study
The use of hydrochlorothiazide (HCTZ) was not associated with increased overall risks of keratinocyte carcinoma or melanoma when compared with angiotensin-converting enzyme inhibitors (ACEIs). However, elevated risks of keratinocyte carcinoma and melanoma were observed with longer durations of use (≥10 years) and higher cumulative doses (≥100,000 mg) of HCTZ, particularly when compared with calcium channel blockers (CCBs).
Q19-05Utilization of angiotensin receptor blockers (ARBs) in Canada
In 2018/19, Health Canada, the US FDA, and other regulatory agencies issued recalls of N-nitrosodimethylamine (NDMA)- and N-nitrosodiethylamine (NDEA)-contaminated angiotensin receptor blockers (ARBs). Despite timely dissemination of these safety communications, little is known about how prescribers and patients responded to the notices.
Q20-02_CDMComparison of pregnancy outcomes of patients treated with ondansetron vs alternative antiemetic medications in a multinational, population-based cohort
In this large study of 4,103,695 pregnancies, ondansetron use during pregnancy was not associated with increased risks of fetal death, spontaneous abortion, stillbirth, or major congenital malformation, when compared with other commonly used antiemetic drugs.
Q16-08Natural coagulopathy and characteristics of its treatment in COVID-19 patients
Recently studies have identified multiple abnormalities of coagulation in many COVID-19 patients. The factors associated with the development of thrombosis in patients with COVID-19 have not been fully evaluated and so the understanding of the determinants of thrombotic events in COVID-19 is important to reducing their risk.